https://www.selleckchem.com/products/gsk621.html
77; 95% CI, 0.59 to 1.01; = 0.06) without statistical significance in type 2 diabetes patients. Compared with placebo, SGLT-2i may reduce the risk of heart failure hospitalization, MACE, and cardiovascular death. Therefore, SGLT-2i may be an ideal choice for type 2 diabetes mellitus patient with heart failure. These results will help inform practitioners, patients, and authorities making appropriate choices in hypoglycemic therapy clinical practice. Compared with placebo, SGLT-2i may reduce the risk of heart failure hospitalization, MACE